Bardoxolone methyl
- Generic Name
- Bardoxolone methyl
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C32H43NO4
- CAS Number
- 218600-53-4
- Unique Ingredient Identifier
- CEG1Q6OGU1
- Indication
Investigated for use/treatment in lymphoma (unspecified), multiple myeloma, and solid tumors.
- Associated Conditions
- -
- Associated Therapies
- -
BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19)
- First Posted Date
- 2020-07-31
- Last Posted Date
- 2022-01-13
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 40
- Registration Number
- NCT04494646
- Locations
- πΊπΈ
NYU Winthrop Hospital, Mineola, New York, United States
πΊπΈNYU Langone Health, New York, New York, United States
πΊπΈHSHS St. John's Hospital (Prairie Education and Research Cooperative), Springfield, Illinois, United States
A Clinical Pharmacology Study of Bardoxolone Methyl in Healthy Adults
- First Posted Date
- 2019-07-18
- Last Posted Date
- 2020-02-05
- Lead Sponsor
- Kyowa Kirin Co., Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT04023903
- Locations
- π―π΅
Medical Corporation Heishinkai OPHAC Hospital, Osaka, Japan
A Study of RTA 402 in Obese Adults
- First Posted Date
- 2019-07-12
- Last Posted Date
- 2020-06-23
- Lead Sponsor
- Kyowa Kirin Co., Ltd.
- Target Recruit Count
- 22
- Registration Number
- NCT04018339
- Locations
- π―π΅
Applied Bio-Pharmatech Kurume Clinical Pharmacology Clinic, Kurume, Fukuoka, Japan
An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE)
- Conditions
- Interventions
- First Posted Date
- 2018-11-21
- Last Posted Date
- 2024-03-19
- Lead Sponsor
- Reata, a wholly owned subsidiary of Biogen
- Target Recruit Count
- 270
- Registration Number
- NCT03749447
- Locations
- π«π·
Chu Grenoble Alpes, Grenoble, France
π«π·Hopital Necker, Universite Paris Descartes, Paris, France
π¦πΊJohn Hunter Hospital, New Lambton, New South Wales, Australia
A Phase 3 Study of Bardoxolone Methyl in Patients With Diabetic Kidney Disease; AYAME Study
- Conditions
- Interventions
- First Posted Date
- 2018-06-08
- Last Posted Date
- 2023-09-26
- Lead Sponsor
- Kyowa Kirin Co., Ltd.
- Target Recruit Count
- 1323
- Registration Number
- NCT03550443
- Locations
- π―π΅
Japan Community Health care Organization Sendai Hospital, Sendai, Miyagi, Japan
Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension RANGER
- First Posted Date
- 2017-03-01
- Last Posted Date
- 2024-02-06
- Lead Sponsor
- Reata, a wholly owned subsidiary of Biogen
- Target Recruit Count
- 261
- Registration Number
- NCT03068130
- Locations
- πΊπΈ
University of Chicago, Chicago, Illinois, United States
πΊπΈMaine Medical Center - Division of Pulmonary and Critical Care Medicine, Portland, Maine, United States
πΊπΈThe Ohio State University Wexner Medical Center, Columbus, Ohio, United States
A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Alport Syndrome - CARDINAL
- Conditions
- Interventions
- First Posted Date
- 2017-01-12
- Last Posted Date
- 2024-02-02
- Lead Sponsor
- Reata, a wholly owned subsidiary of Biogen
- Target Recruit Count
- 187
- Registration Number
- NCT03019185
- Locations
- πΊπΈ
Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, Georgia, United States
πΊπΈCleveland Clinic, Cleveland, Ohio, United States
πΊπΈAkron Nephrology Associates, Akron, Ohio, United States
Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIAT
- Conditions
- Pulmonary Arterial HypertensionPulmonary HypertensionInterstitial Lung DiseaseIdiopathic Interstitial PneumoniaIdiopathic Pulmonary FibrosisSarcoidosisRespiratory Bronchiolitis Associated Interstitial Lung DiseaseDesquamative Interstitial PneumoniaCryptogenic Organizing PneumoniaAcute Interstitial Pneumonitis
- Interventions
- First Posted Date
- 2014-01-15
- Last Posted Date
- 2024-02-05
- Lead Sponsor
- Reata, a wholly owned subsidiary of Biogen
- Target Recruit Count
- 166
- Registration Number
- NCT02036970
- Locations
- πΊπΈ
Mount Sinai, Beth Israel Medical Center, New York, New York, United States
πΊπΈUniversity of California Davis Medical Center - Division of Pulmonary and Critical Care, Sacramento, California, United States
πΊπΈCedars Sinai Medical Center, Beverly Hills, California, United States
A Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Effects of Bardoxolone Methyl on Body Composition in Patients With Stage 4 Chronic Kidney Disease and Type 2 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2012-08-01
- Last Posted Date
- 2024-02-02
- Lead Sponsor
- Reata, a wholly owned subsidiary of Biogen
- Registration Number
- NCT01655186
Single-Dose, Open-Label Pharmacokinetic Study of Bardoxolone Methyl in Subjects With Mild, Moderate, and Severe Hepatic Impairment and Normal Hepatic Function
- First Posted Date
- 2012-03-27
- Last Posted Date
- 2024-02-02
- Lead Sponsor
- Reata, a wholly owned subsidiary of Biogen
- Target Recruit Count
- 34
- Registration Number
- NCT01563562
- Locations
- πΊπΈ
Duke University, Durham, North Carolina, United States
πΊπΈUniversity of Miami School of Medicine, Miami, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.